Domov › Rak dojke › Maryland › Baltimore

Klinične študije za Rak dojke v Baltimore, MD

47 študij za Rak dojke išče udeležence na lokacijah v Baltimore in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Vključevanje udeležencevFaza 3

Mercy Medical Center, Baltimore

Starost 18–100 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci

Mercy Medical Center, Baltimore
Sinai Hospital of Baltimore, Baltimore
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
in še 2

Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Vključevanje udeležencevFaza 2

Johns Hopkins University, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06172478

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

Vključevanje udeležencevFaza 3

Maryland Proton Treatment Center, Baltimore

Starost 19 in več · Ženske · Posodobljeno 29. sep. 2026 · NCT05856773

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Vključevanje udeležencevFaza 2

Maryland Proton Treatment Center, Baltimore

Starost 50 in več · Ženske · Posodobljeno 29. sep. 2026 · NCT01766297

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Vključevanje udeležencevFaza 3

Mercy Medical Center - Baltimore ( Site 0015), Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06966700

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Vključevanje udeležencevFaza 3

Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06312176

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Vključevanje udeležencevFaza 3

Clinical Trial Site, Baltimore
Clinical Trial Site, Baltimore
Clinical Trial Site, Annapolis · 22 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07085767

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Vključevanje udeležencevFaza 1

United Theranostics, Glen Burnie · 9 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07213791

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Vključevanje udeležencevFaza 2

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT07340541

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Vključevanje udeležencevFaza 3

Saint Agnes Hospital, Clinical Research Center, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07173751

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Vključevanje udeležencevFaza 3

Mercy Medical Center, Baltimore
Ascension St. Agnes Hospital, Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT06492616

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Vključevanje udeležencevFaza 1/2

Research Site, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT05123482

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Vključevanje udeležencevFaza 1/2

Maryland Oncology Hematology - Annapolis, Annapolis · 22 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT07100106

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Vključevanje udeležencevFaza 3

Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06982521

Cardiometabolic Screening Program

Vključevanje udeležencev

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT05386719

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Vključevanje udeležencevFaza 2

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Starost 18 in več · Ženske · Posodobljeno 3. sep. 2026 · NCT06245889

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Vključevanje udeležencevFaza 3

University of Maryland, Baltimore
Velocity Clinical Research, Annapolis · 22 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06790693

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Vključevanje udeležencevFaza 3

University of Maryland/Greenebaum Cancer Center, Baltimore
Mercy Medical Center, Baltimore
Greater Baltimore Medical Center, Baltimore
in še 8

Starost 18–60 · Ženske · Posodobljeno 2. sep. 2026 · NCT05879926

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Vključevanje udeležencevFaza 2

The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT06764940

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Vključevanje udeležencevFaza 3

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT06500481

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Vključevanje udeležencevFaza 2/3

Local Institution - 1035, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT06926868

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Vključevanje udeležencevFaza 3

Maryland Oncology Hematology, Annapolis · 22 mi stran

Starost 18–100 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT05232916

E-Mindfulness Approaches for Living After Breast Cancer

Vključevanje udeležencevFaza 3

Maryland Proton Treatment Center, Baltimore
University of Maryland/Greenebaum Cancer Center, Baltimore
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
in še 7

Starost 18–50 · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT06748222

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Vključevanje udeležencevFaza 2

The John Hopkins Hospital, Baltimore

Starost 8 in več · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT05503797

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Vključevanje udeležencevFaza 2

Sidney Kimmel Comprehensive Cancer Center, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 2. jul. 2026 · NCT02422641

EXoPERT EMERALD Clinical Study

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci

John Hopkins University, Baltimore

Starost 45 in več · Vsi spoli · Posodobljeno 1. jul. 2026 · NCT07186296

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Vključevanje udeležencevFaza 3

Johns Hopkins Kimmel Cancer Center, Baltimore

Starost 18 in več · Vsi spoli · Posodobljeno 22. jun. 2026 · NCT05696626

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Vključevanje udeležencevFaza 1

Johns Hopkins University, Baltimore

Starost 18–99 · Vsi spoli · Posodobljeno 17. jun. 2026 · NCT05029999

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Vključevanje udeležencevFaza 1

Advanced Molecular Imaging and Therapy, Glen Burnie · 9 mi stran
United Theranostics - Chesapeake, Glen Burnie · 9 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 11. jun. 2026 · NCT05283330

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

Vključevanje udeležencevFaza 1

United Theranostics, Glen Burnie · 9 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 3. jun. 2026 · NCT07311993

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Vključevanje udeležencevFaza 3

Mfsmc-Hjwci, Baltimore
Maryland Oncology Hematology P.A., Annapolis · 22 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 6. maj 2026 · NCT07062965

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Vključevanje udeležencevFaza 3

University of Maryland/Greenebaum Cancer Center, Baltimore
Greater Baltimore Medical Center, Baltimore
Saint Agnes Hospital, Baltimore
in še 7

Starost 50–70 · Vsi spoli · Posodobljeno 23. apr. 2026 · NCT04852887

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Vključevanje udeležencevOpazovalna študija

University of Maryland/Greenebaum Cancer Center, Baltimore
Sinai Hospital of Baltimore, Baltimore
UM Saint Joseph Medical Center, Towson · 8 mi stran
in še 1

Starost 18 in več · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06418204

The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

Vključevanje udeležencev

Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns Hopkins, Baltimore
Johns Hopkins Bayview, Baltimore
Johns Hopkins Kimmel Cancer Center at Greenspring Station, Lutherville · 9 mi stran

Starost 18 in več · Ženske · Posodobljeno 23. feb. 2026 · NCT05780814